An extensive, although largely forgotten, literature addresses the utility of adjunctive corticosteroid therapy in the management of tuberculosis. Corticosteroid therapy probably improves neurological outcomes of, and decreases mortality due to, tuberculous meningitis of moderate severity. Although therapy for tuberculous pericarditis is simplified (with less need for operative intervention) by adjunctive corticosteroid administration and there are fewer deaths, the incidence of subsequent constriction is not changed. The signs and symptoms of typical reactivation tuberculous pneumonia, tuberculous pleurisy, and probably primary tuberculous disease (with lymphadenopathy) seem to decrease rapidly with corticosteroid therapy, although no differences in final outcomes have been observed. Corticosteroid regimens used in most studies varied greatly in duration and dosage and generally caused significant side effects. Corticosteroids do not appear to diminish the efficacy of adequate antimycobacterial therapy. Adjunctive corticosteroid therapy appears to offer significant short-term but (other than for tuberculous meningitis and effusive pericarditis) minimal long-term benefit for patients with tuberculosis.
Despite the availability of effective chemotherapy for tuberSimilar considerations have prompted investigators to conduct a range of studies over the past 40 years into the utility culosis (TB), significant morbidity and mortality due to this disease continue to occur. While multiple factors complicate of adjunctive corticosteroid usage in therapy for TB. A perusal of recent reviews of therapy for TB suggests that this older body therapy for TB, slow or even paradoxical responses to effective antibiotics, especially in far-advanced disease, have long hamof data, especially that addressing adjunctive use in pulmonary forms of the disease, has been largely ignored. We critically pered clinical efforts [1, 2] . As better antimycobacterial agents became available and clinical responses became more certain, reviewed the published literature addressing corticosteroid usage in therapy for TB. Where the data were adequate to deterthe often tardy pace of clinical improvement continued to frustrate both patients and physicians. More efficiently bactericidal mine whether corticosteroids are useful or not for a particular tuberculous syndrome, we develop reasonable recommendaagents -such as isoniazid -may actually cause more profound acute neurological deterioration in patients with meningeal TB tions. Areas where inadequate data addressing corticosteroid therapy have been generated are also discussed, and the avail-(with more pronounced brain swelling), presumably attendant to more rapid organism killing [3] . able data are presented. Local signs and symptoms of TB are at least partially caused by the host's inflammatory response to the presence of the Mycobacterium tuberculosis bacillus [4] . It is probable that the Historical Background systemic wasting syndrome associated with progressive TB is Early investigations into the effect of corticosteroid adminisalso related to the host's inflammatory response, as mediated tration on M. tuberculosis infection were performed by using through excessive cytokine production [5] . It is reasonable to animal models of TB. Corticosteroid administration markedly postulate, therefore, that potent antiinflammatory agents such enhanced the virulence of M. tuberculosis in these studies, in as corticosteroids, known to suppress a myriad of inflammatory which no specific antituberculous agent was employed [6, 7] . responses, may prove effective as adjunctive therapy in the When antituberculous agents were developed, repeated studies management of TB.
suggested that the deleterious effects of corticosteroid administration on M. tuberculosis infection were, for the most part, [9] , but coadministration of corticosteroids with antitubercusis (Fisher's exact test; P õ .05, statistical significance), the results of which are reported here. Several of the later studies lous agents could improve outcomes [10 -14] . These data were suggestive enough to prompt the initiation of controlled studies included statistical analyses of their own data, the results of which are reported here. investigating the utility of adjunctive corticosteroid therapy for clinical TB.
Results Methods

Pulmonary TB
The English language medical literature was searched through a MEDLINE (National Library of Medicine) review
Data from 11 randomized trials [15 -26] that examined the effect of adjunctive corticosteroid therapy on pulmonary TB (1966 to 1996) of pertinent index topics (tuberculosis, corticosteroids, and related words). References obtained both from are presented in table 1. Although only four trials were doubleblind, three other trials recorded radiographic responses in a these articles and from book chapters were screened to compile a comprehensive collection of pertinent primary literature.
blinded fashion, and all studies reported at least adequate matching of groups. For a study to be accepted for scrutiny in the following sections, both a study group (using adjunctive corticosteroid
The first randomized, controlled trial to examine the effect of adjunctive corticosteroid therapy was from Scotland in 1957 therapy) and a control group (no use of corticosteroid therapy) had to be defined, the comparability of the groups had to be [16] . Despite faster radiographic clearing in the corticosteroid recipients, no differences between the groups were seen in the addressed, adequate antituberculous therapy must have been administered, and a defined course of corticosteroid therapy rate of cavity closure or in the incidence of side effects of the antituberculous drugs. Transient and generally mild radiologimust have been employed. The use of what would now be considered suboptimal antituberculous therapy in earlier trials cally evident deterioration occurred in seven study patients (16%) following discontinuation of corticosteroid therapy. did not disqualify a study for scrutiny if both study and control groups received the same regimen, since an analysis of the In 1959, Weinstein and Koler [17] reported a randomized, double-blind investigation demonstrating that radiographically utility of steroids can still probably be performed. Most studies were blinded, but many had nonblinded aspects (e.g., blinded evident abnormalities cleared significantly faster in corticosteroid recipients. Bell et al. [15] , in 1960, reported the results radiographic readings in a nonblinded study). We elected to present only the ''harder'' endpoints in these studies (such as of a nonblinded study where the clinical symptoms in the most severely ill patients, in particular, assigned to the corticosteroid time to negativity of sputum culture, or death), i.e., endpoints for which it would have been difficult to introduce bias. The group abated significantly faster than did those in the severely ill control subjects (P õ .01). However, these responses were following data were recorded: the type of study, method of randomization (if used), number of patients, and antitubercudetermined by nonblinded observers. Extensive comparisons were made in this study of changes in sputum volume, sputum lous and corticosteroid regimens.
Side effects of corticosteroids were recorded, but many incharacter, and rates of conversion of sputum cultures to negative, revealing no differences between groups. vestigators did not document these effects as vigilantly as the intended beneficial effects. The few studies that attempted to The U.S. Public Health Service Tuberculosis Therapy trial, a multicenter study published in 1960 [18] , is still the largest accurately record side effects (e.g., [15] ) reported them to be both frequent and occasionally severe. There is a strong suspisingle investigation to address the question of the efficacy of steroids on TB. In nonblinded fashion, patients received either cion, then, that side effects in other studies were grossly underreported. ''Rebound'' phenomenon, or the temporary flaring placebo or one of two prednisolone regimens (5 weeks vs. 9 weeks). Few beneficial or detrimental effects of the low dosages of symptoms, signs, or radiographically evident changes upon tapering or discontinuing corticosteroid therapy, was recorded, of prednisone used (20 mg/d at initiation) were seen in this trial. Although side effects were rare, there also appeared to but, in general, this phenomenon was a minor problem and easily treated by the reinitiation of corticosteroid therapy at be no protective effect from the allergic side effects of the antibiotics. low doses.
Outcomes were recorded and analyzed by the following:
In an attempt to avoid eventual complications of steroid withdrawal, Angel et al. [19] treated study patients with adrenoacute responses (the effect on local or systemic signs and symptoms within the first days, up to 2 weeks), long-term responses corticotropic hormone (ACTH). While clinical symptoms and radiographically evident conditions abated faster in corticoste-(including eventual fibrotic complications), mortality, and laboratory-defined responses (e.g., changes in CSF in patients with roid recipients, this study is significant in that it is the only investigation to describe a slower rate of conversion of sputum meningeal TB or the rate of conversion of sputum cultures to negative in cases of pulmonary TB). Few of the earlier studies cultures to negative among steroid recipients (significant by 3 months, although comparable by 6 months). No clinically included any formal analysis of their data. When adequate categorical data were reported, we performed statistical analysignificant changes in pulmonary function tests (vital capacity, given Rif) had slower rate of sputum culture conversion as prednisone in this setting, more patients receiving ACTH malities improved much more rapidly in steroid recipients; rebound reactions were common but ''mild,'' with no radiotherapy required interruption of treatment because of side effects (primarily neuropsychiatric reactions).
graphically evident worsening. Chest radiographs by 4 and 6 months, lung volumes, flow rates, arterial-alveolar gradients, The study reported by McLean [22] in 1963 is one of the four trials investigating pulmonary function parameters in addiand diffusing capacity of carbon monoxide were comparable between groups. Almost identical results were found in the tion to clinical and radiographic indicators [19, 22, 23, 25] . General clinical conditions and radiographically evident abnorstudy by Marcus et al. [23] in the same year, which demon-strated rapid early clinical and radiographically evident imsteroid therapy when used with subadequate treatment regimens for animals [27, 28] or humans [9] . provement in steroid recipients with eventual comparability of symptoms, radiographs, and pulmonary function tests (includIn summary, several controlled studies have suggested that the clinical conditions of patients with pulmonary TB treated ing measurements of flow, volume, oxygenation, and carbon monoxide diffusing capacity).
with corticosteroids improve more rapidly overall than do those of control patients, an effect that may be more pronounced in In a double-blind trial in 1965, Johnson et al. [24] demonstrated much faster clinical and radiographically evident impatients with severe disease. The data suggest an absence of long-term beneficial effects of corticosteroid usage (in particuprovement in the conditions of patients given low doses of corticosteroids for prolonged durations. These differences were lar, on mortality or chronic restrictive disease). Other than rates of cavity closure, which do not seem to be affected by particularly significant in advanced cases. Radiographically evident ''rebound'' phenomena occurred following completion of corticosteroid usage, faster radiologically evident responses are usually seen with the adjunctive use of corticosteroids. These the steroid regimen in 60% of cases (especially in cases of advanced disease); symptoms of clinical ''rebound'' phenomena radiographically evident improvements are of uncertain significance to the individual patient. A minority of patients may occurred briefly in one-half of cases. At least moderate abatement in cough and sputum production was more often seen in have mild ''rebound'' phenomena if corticosteroid therapy is discontinued too abruptly. When corticosteroids are given with corticosteroid-treated patients (39 [81%] of 48) than in control patients (28 [61%] of 46) (P õ .05). Unusually complete 5-year adequate antituberculous therapy, the rate of clearance of M. tuberculosis from the sputum is not reduced, nor is the follow-up data were available in this study through the Veterans Administration system; these data revealed that control patients rate of long-term cure (even with short-course therapy). As expected, corticosteroid administration in the face of inadewere more likely than corticosteroid recipients to have worsened or to have died of TB relapses or related respiratory illnesses quate chemotherapy appears to be harmful to the patient. (bronchitis, respiratory insufficiency, or pneumonia) (seven of 50 vs. one of 52, respectively; P õ .025).
Tuberculous Meningitis
Malik and Martin [25] reexamined the effect of corticosteroid therapy on pulmonary function in 1969. Although abate-
The trials investigating the effects of corticosteroid therapy on meningeal TB suffer from differences in study design, corticostement of symptoms and radiographically evident improvement were more pronounced in corticosteroid recipients, an effect roid regimens, and endpoints measured. In addition, not all patients included in these series were definitively proven to have on multiple pulmonary function parameters was not obvious (including the forced vital capacity, maximal expiratory flow tuberculous meningitis on the basis of a positive culture or a stain of a tissue biopsy specimen revealing granulomas with acidrate, nitrogen washout, and resting and exercise blood gas levels determined at baseline, 6 months, and 12 months). The fast bacilli. However, when the diagnosis was not culture or smear proven, the appropriate clinical picture, positive skin tests, maximal voluntary ventilation in corticosteroid recipients was better at 6 months, but there was no difference between groups and responses to directed antituberculous chemotherapy were generally present, and the inclusion of these patients in each of at 12 months. In contradistinction to Angel et al. [19] , conversion of sputum cultures to negative was actually significantly the following studies seems clinically reasonable. Following an earlier positive but anecdotal experience faster (at 8 and 12 weeks) in the corticosteroid group.
While conducting a very large trial comparing short-course with use of corticosteroids in the treatment of TB meningitis [29 -31] , a total of seven controlled trials, of varying degrees regimens (with or without rifampin) in Madras, India, the Indian Tuberculosis Research Centre [26] included a nonblinded of rigor, were performed to examine this issue [32 -38] (table  2) . In a 1955 trial, Ashby and Grant [32] enrolled slightly randomization of patients with pulmonary TB to an 8-week prednisolone arm or a control arm. While little data on immedisicker patients (according to Medical Research Council criteria [39] ) in the corticosteroid group by using the peculiar randomate clinical responses were given in this report, the study is significant in two ways. First, it is the only trial of adjunctive ization of sequential group assignment. No laboratory parameters were reported, although comment was made that CSF abcorticosteroid usage with short-course therapy, resulting in comparably low rates of relapse in steroid and control groups.
normalities and symptoms both abated much more quickly in corticosteroid recipients. No corticosteroid recipient, as comSecond, large numbers of patients from whom isolates of M. tuberculosis resistant to both isoniazid and streptomycin were pared with four of six control patients, had neurological sequelae (including one death) (P Å .06, our statistical analysis). recovered before the trial were entered into the study. These patients were then treated with two effective agents for only Voljavec and Corpe [33] elaborately analyzed retrospective data for all 33 patients admitted to Battey State Hospital (Geor-2 months, and only one effective agent (pyrazinamide) was administered for the remainder of their courses. Analysis regia) over a 6-year period for the treatment of moderate to severe tuberculous meningitis [39] . Although 11 other patients with vealed that corticosteroid-treated patients responded less frequently to antibiotic therapy than did control patients, a result early disease were not scrutinized, an important observation about these patients with early disease was recorded: all surthat recapitulated previous observations on adjunctive cortico-/ 9c3d$$oc26 09-19-97 08:24:09 cida UC: CID vived without sequelae, whether given steroids (three patients) 1963 [35] . Unfortunately, the randomization may have failed: one-half (nine of 18) of the controls were young children with or not (eight patients). The groups were comparable. While no laboratory or acute clinical parameters were studied, long-term poorer prognoses, while only three (16%) of 19 corticosteroidtreated patients had poorer prognoses. As expected, a greater survival was clearly greater in corticosteroid recipients. When all patients were stratified by severity of disease, those most ill proportion of patients in the control group (67%) had advanced disease at presentation than did corticosteroid recipients (42%). did poorly with or without corticosteroid therapy; the greatest differential survival between groups was demonstrated for
No difference was seen in time to normalization of CSF parameters, in permanent neurological disability, or in death. The those patients with intermediate severity (and especially those with spinal block according to the authors' definition) (one of duration of the corticosteroid regimen was the shortest used in any comparative study, and (if interpretable at all) these data 13 corticosteroid recipients died vs. six of 11 control patients; P õ .025, our statistical analysis). This study was the first suggest that a course longer than 2 weeks may be necessary for an effect. of two investigations [33, 34] to suggest that corticosteroid administration was not needed in mild disease and was not A second randomized, double-blinded trial from Calcutta was reported in 1969 [36] . A nonsignificant trend toward useful in very late disease.
The first randomized, double-blind trial to examine the efgreater survival was seen in the corticosteroid group In summary, seven trials of various degrees of rigor have investigated the effects of corticosteroids on tuberculous menthat corticosteroids were useful for reducing cerebral edema but that the evident antiinflammatory effects were not useful ingitis. Five of these trials, including the largest and best analyzed study [34] , demonstrated an advantage of adjunctive corin the reduction of long-term sequelae.
A more recent randomized, double-blind trial from Colombia ticosteroid therapy over standard therapy for survival, frequency of sequelae, or both. When examined, CSF abnorused sequential analysis of matched pairs to evaluate the efficacy of corticosteroid therapy in the reduction of mortality due malities and elevated CSF pressures resolved significantly faster in corticosteroid recipients. Both studies that stratified to tuberculous meningitis [37] . This analysis demonstrated that the corticosteroid group had a statistically significant advantage illness by severity at presentation [33, 34] noted the lack of effect of corticosteroids on either early disease or late disease for short-term survival but that neurological sequelae in both groups at discharge appeared comparable. Long-term follow-(coma), but a significant benefit for patients with intermediate disease (drowsiness, single cranial nerve paresis, or hemipareup could not be done. The magnitude of the effect of corticosteroids could not be determined in this study, and no analysis sis). Three studies with shorter CS regimens (2 -4 weeks) [35, 36, 38 ] demonstrated disappointing results; those studies with of subsets to identify patient groups particularly amenable to corticosteroid therapy was presented.
longer regimens (4 weeks to ''months'') [32 -34, 37] demonstrated significant beneficial effects. A regimen of dexamethaGirgis et al. [38] performed a randomized study to determine the effects of corticosteroids on the appearance of ocular nerve sone at 8 -12 mg/d [34, 38] , or a prednisone equivalent [37] , seemed as effective as, and had fewer side effects than, higher abnormalities in patients with tuberculous meningitis. Despite a trend toward more severe neurological involvement in cortidoses [37] . The use of corticosteroids to alleviate elevated intracranial pressure seemed to be accepted even by the authors costeroid recipients, there was a nonsignificant trend toward longer survival in the corticosteroid group (especially in paof negative studies [36] . tients with mild and moderate [drowsy] neurological involvement [17 (68%) of 25 corticosteroid recipients survived vs. 22
Tuberculous Pericarditis (58%) of 38 control patients]) and a nonsignificant trend toward fewer ocular complications in the corticosteroid group (two of The efficacy of corticosteroid therapy for tuberculous pericarditis may differ for the different physiological stages of the 27 survivors) than in the control group (seven of 28 survivors). While significantly more control patients than corticosteroiddisease (effusive, effusive-constrictive, and constrictive), but too often reports do not classify patients by these stages. In treated patients had optic atrophy, these numbers were very small (four of 28 vs. zero of 27, respectively; P õ .05).
addition, constriction is a late complication of the effusive or effusive-constrictive stage, but patients in many investigations These investigators from Egypt subsequently performed the largest randomized (but nonblinded) study of the use of corticohave not been followed up long enough to detect its development. steroid therapy for tuberculous meningitis [34] . Corticosteroidtreated patients for whom cultures were positive had less morEven the best of the retrospective studies examining this question [40, 41] are characterized by the absence of group tality than controls, whether all patients were considered (32 [43%] of 75 corticosteroid recipients died vs. 50 [59%] of 85 comparisons and poorly defined endpoints. An exception is the study by Rooney et al. [42] in which data on 28 patients were controls, respectively; P õ .02) or just those patients surviving §10 days (seven [14%] of 50 corticosteroid recipients died vs. collected (table 3) . Eighteen patients received corticosteroid therapy in addition to antituberculous therapy in a nonrandom-17 [33%] of 52 controls, respectively; P õ .02). No difference was seen when patients who were admitted in comas were ized but well-matched manner. Patients treated with corticosteroids had a more rapid decrease in their pericardial effusion considered, but the survival of those patients who were drowsy at the time of admission was greater in the corticosteroid group than did controls (5 vs. 12 weeks for the heart size to return to normal, respectively; no test for significance applied). Four than in the control group (23 [85%] of 27 vs. 21 [60%] of 35, respectively; P õ .02). Too few patients with minimal disease patients in each group required pericardiectomy, presumably for control of reaccumulation of fluid. The conditions of 14 of were admitted to be evaluated. While neurological complications (such as hemiparesis or hydrocephalus) were seen at the 18 patients in the corticosteroid group improved without surgery compared with four of 10 patients in the control group time of admission with comparable frequencies in both groups, fewer new complications occurred after admission in the corti-(P Å NS, our statistical analysis). Four of 10 control patients died, whereas none of 18 in the corticosteroid group died costeroid group than in the control group ( (P õ .01, our statistical analysis). Too few patients progressed low jugular venous pressure (õ5 cm; P õ .05) or unrestricted physical activity (P õ .05), was seen in patients in the corticoto late constriction to discern differences in this parameter between groups. steroid group. However, there was no difference between the two groups in the development of constrictive pericarditis. Strang et al. [43] performed the only prospective, randomized, double-blind study investigating the utility of corticosteIn summary, the use of corticosteroid therapy for acute effusive tuberculous pericarditis appears to decrease the amount roid therapy for effusive pericarditis. Corticosteroid therapy significantly reduced the need for repeated pericardiocentesis of effusion and the reaccumulation of fluid. Therefore, fewer invasive measures are needed to control fluid accumulation. for control of fluid accumulation (seven of 76 corticosteroid recipients vs. 17 of 74 controls; P õ .05) and reduced the risk Overall mortality is decreased with the use of corticosteroids in this setting, probably secondary to the control of hemodyof death due to pericarditis (two of 76 corticosteroid recipients vs. 10 of 74 controls; P õ .05). Three corticosteroid recipients namically threatening effusion. Although corticosteroid use in the later effusive-constrictive stage seems to speed symptomcompared with seven control patients required emergent pericardiectomy to prevent the development of cardiac tamponade atic and hemodynamic recovery, it does not significantly reduce the risk of death. The progression from any stage to chronic (P Å NS). There was no difference in the incidence of progression to constriction between the two groups.
constrictive pericarditis does not seem to be inhibited by corticosteroid use. Strang et al. [44] also performed a similar quality study of patients in the later effusive-constrictive phase of tuberculous pericarditis. By the recorded results of physical examination, Tuberculous Pleuritis electrocardiograms, and echocardiographic criteria, it is difficult to determine the extent to which constriction had already Ten trials of various degrees of experimental rigor that addressed steroid therapy for tuberculous pleural effusions have occurred in these patients. Nonsignificant differences were apparent between corticosteroid recipients and controls for death been published. [55 -57] ). It is unclear whether acute complications (pain, fever, and dyspnea) or At the University of Helsinki, 66 patients were enrolled in a nonrandomized study [49] in which 28 were assigned to chronic local complications (restriction) occur with similar frequency in all groups, yet no group classifications are presented treatment with tapering doses of triamcinolone (without thoracentesis) and 28 received serial therapeutic thoracenteses. Dein these studies. Second, cases are usually diagnosed clinically, without confirmatory cultures; although most cases would be spite the lack of therapeutic drainage, large effusions resolved as fast in corticosteroid recipients as in control (thoracentesis) accepted by standard criteria, incorrectly diagnosed cases would confound results. Last, though the main chronic complipatients; small effusions resolved significantly faster. At 6 and 12 months, significantly more patients in the corticosteroid cation of tuberculous pleurisy is fibrosis with restrictive lung disease, this endpoint was scrutinized only once in a nonintergroup had ''good'' radiographic results; whether these differences were clinically significant for the patients was not adpretable study [52] . In the other studies, the usual long-term follow-up was the radiographic determination of the presence dressed.
The only randomized, prospective, double-blind study ador absence of pleural reactions, by themselves of uncertain significance to the patient.
dressing this question appeared in 1988 [50] . The steroid regimen was not straightforward, being tapered according to radioThe first trial to address this issue appeared in 1958 [45] ; this study included 14 controls (13 consecutive patients ''just graphic markers (e.g., tapered ''by 2 / 3 '' for effusions that had almost resolved), and the average tapering occurred over 2 -3 before'' the start of corticosteroid therapy and one later patient with a corticosteroid contraindication) and 16 study patients months. The grouped symptom complex of ''fever, chest pain, and dyspnea'' resolved much faster in corticosteroid recipients (the next 16 patients who received various steroid regimens for 2 -3 months). Although the resolution of effusion volumes than in controls (2.4 days vs. 9.2 days, respectively; P õ .05).
Radiographically evident pleural effusions also resolved much was remarkably faster in corticosteroid-treated patients than in the controls, no other endpoints were recorded.
faster in corticosteroid recipients than in controls (mean duration: 55 days vs. 123 days, respectively; P õ .01). Mathur et al. [46] in 1960 used the interesting approach of local instillation of hydrocortisone into involved pleural spaces In summary, several studies have demonstrated beneficial effects of adjunctive steroid use with antituberculous chemo-(in the absence of other systemic steroid therapy). Acute toxicities were markedly reduced in the steroid group than in the therapy for pleural effusions. The most recent study, of good design, supported the positive findings from earlier nonblinded controls, as were the amounts of effusion (resolution within 15 days: 18 [72%] of 25 vs. zero of 25, respectively; P õ .0001, studies. The most salutary effects appeared to be on acute symptoms (usually defined as pain, fever, and dyspnea). The our statistical analysis). Long-term comparisons (limited to pleural thickening) were poorly defined. In the same year, current data suggest that corticosteroids possess no clinically significant efficacy for the prevention of the chronic endpoint of Fleishman et al.
[47] conducted a randomized trial of the treatment of pleural effusions in South African mine laborers. Antifibrosis (with consequent restrictive lung disease). All studies suggested a diminution of radiographically determined persistuberculous drug -treated patients had slow resolution of effusion (four [21%] of 19 had resolution within 8 weeks), although tent scarring in corticosteroid-treated patients, but clinical correlations were lacking. Regimens varied from prednisone faster resolution was seen in patients treated with both antituberculous drugs and corticosteroids (12 [60%] of 20; equivalent dosages of 20 -40 mg/d for 4 -8 weeks, with no evidence that higher doses or longer courses were more effec-P Å .02, our statistical analysis). Significantly faster ''overall improvement'' (the resolution of fever, pain, and malaise) was tive. Systemic corticosteroid therapy seemed more effective than local instillation in the two studies in which this question seen in the corticosteroid-treated patients as well. This trial lasted only 8 weeks.
was investigated. Menon [48] reported the effect of steroid administration on a series of patients with considerable morbidity (43 of 49 conPrimary TB secutive patients had effusions at the third rib or higher). Different corticosteroid regimens were given, and the trial was not Two controlled studies of classic pediatric primary disease have addressed the utility of steroid use in the control of medirandomized, with patients with more serious disease (larger pleural effusions) deliberately assigned to the steroid groups.
astinal lymphadenopathy associated with primary TB (table 5) . In a small study, Keidan and Todd [58] randomized alternate Resolution of pleural effusions was significantly faster in steroid-treated patients than in controls (resolution by 4 weeks: admissions to adjunctive triamcinolone for 10 weeks. In a large, double-blind trial in 1963, Nemir et al.
[59] studied nonresolving luminal granulomatous disease) may reflect hypersensitivity to the organism and anecdotally seems responthe effect of very high initial doses of prednisone (tapering over 6 weeks) on the bronchoscopic endpoint of size of endosive to corticosteroid administration [61, 62] . bronchial extension of lymphadenopathy (determined 4 weeks after steroid therapy was discontinued). The conditions of 39 (67%) of 58 corticosteroid-treated patients improved compared Tuberculous Lymphadenitis with 27 (46%) of 59 control patients (P õ .05). Neither acute An adjunct to antituberculous therapy for peripheral lymphnor chronic symptoms were investigated. Side effects were adenitis is needed, in that as many as one-third of involved carefully monitored and were distressingly common. Both of node groups ''flare'' with an exacerbation of pain and swelling these studies showed no difference in the clearing of positive following the initiation of chemotherapy [63] . Unfortunately, cultures between groups.
despite comment that oral steroids may be useful in this setting In summary, it appears that steroids are effective in rapidly [64] , no controlled study has addressed the issue, and one is reducing mass effects from mediastinal lymphadenopathy in left with extrapolations from the data on mediastinal lymphadepatients with primary TB and may therefore decrease local nopathy (see above [58, 59] ). obstructive complications (although this latter issue was not specifically addressed in the studies). Lower doses may be as effective as very high doses. Long-term follow-up, for evaluat-
Miliary TB
ing relapses or the evolution of stenotic or ectatic segments, was not reported in these studies.
The only study of miliary TB that described patient characteristics sufficiently to allow a comparison of control and corticosteroid groups was reported from China in 1981 [65] (table   Endobronchial TB 6). Nine (33%) of 27 corticosteroid recipients compared with five (18%) of 28 controls had meningeal involvement, possibly Adjunctive corticosteroids have been used to treat endobronchial TB in an attempt to reduce eventual bronchial stenosis;
skewing the results in favor of the control group; the randomization method was unclear. Data on mortality showed a nonno data on efficacy from controlled trials exist (other than those on the childhood subset of lymphatic extension into the significant trend toward better outcome for the steroid group than for controls (death: two of 27 vs. five of 28, respectively). bronchial lumen [58, 59] ), and even anecdotes are not impressive [60] . A rare syndrome of endobronchial TB (presenting A more recent retrospective study that included an analysis of the effect of steroids on mortality in childhood miliary TB is many weeks after the initiation of antituberculous therapy as / 9c3d$$oc26 09-19-97 08:24:09 cida UC: CID NOTE. INH Å isoniazid; NS Å not significant; PAS Å para-aminosalicylic acid; Prd Å prednisone; Stm Å streptomycin; 1 Å for. * Time to conversion of culture to negative. † Physiological or radiographic parameters measured within days to õ3 months of start of therapy. ‡ Physiological or radiographic parameters measured after 3 months from start of therapy.
uninterpretable [66] , because no comparison at all of groups tuberculous regimen,'' there seem to be insufficient data from their, or any other, study to recommend this as yet. was given.
Therefore, although data suggesting a lack of effect of steroids on acute miliary TB have been presented, enough probLaryngeal TB lems exist with the matching of experimental groups that these data are not interpretable.
Despite several reports citing a remarkable diminution in upper airway symptoms when some patients with laryngeal TB received steroid therapy [10, 68, 69] , no controlled trial has Peritoneal TB been performed, and patients' conditions normally improve rapidly without steroid treatment [69, 70] . Singh et al. [67] randomized every other patient with peritoneal TB to receive a prolonged (4-month) course of prednisone (table 7) . No specific comment on the comparability of groups HIV-Associated TB was made. The lack of an acute salutary effect of steroids may be explained by the rapid decrease in symptoms seen in both
No studies have separately examined the use of corticosteroid therapy for HIV-infected patients with TB. Although groups. None of 23 corticosteroid-treated patients had chronic fibrotic complications compared with four of 24 controls severe miliary disease with acute respiratory distress syndrome [71, 72] , as well as rapid progression to respiratory failure [73] , (P Å NS, our statistical analysis). Although these investigators emphasized the ''desirability of adding steroids to the antihas been observed in HIV-infected patients, only anecdotal [74] have been forthcoming, and the in that study, and although rifampin and streptomycin levels in CSF were not consistently above the MIC for corticosteroidadjunctive use of corticosteroid therapy for HIV-related TB must be considered untested. treated patients, they did not differ from levels in controls. Taken together with the empirical observations from large trials as outlined above, these data suggest that the adjunctive use Discussion of corticosteroids does not impair tuberculocidal activity in CSF. Perusal of four decades of literature on the effects of adjunctive steroid therapy for TB revealed that a tradition of Corticosteroids have been used to suppress hypersensitivity reactions to necessary medicines [77, 78] . Similar data, which careful clinical investigation has been established by earlier researchers. Adequate data now exist that address the effect of are consistent and occasionally striking, have also been generated for the treatment of hypersensitivity reactions to antitubercorticosteroids on the course of TB of the lung, pleura, meninges, and pericardium and probably primary disease. Unfortuculous agents [79 -82] . Three controlled studies [16, 18, 24] specifically examined this effect, and, although it is not clear nately, less than adequate data on tuberculous involvement of other organ systems exist.
how vigorously hypersensitivity side effects were actually sought, in general, no obvious protective effect of cortico-A recurrent theme has been the persistent efficacy of adequate antimycobacterial therapy in clearing positive cultures steroids was observed in these studies. Doses of 20 -80 mg of prednisone equivalents were generally used (with 60 mg usueven when corticosteroids were used. In eight of 10 studies of pulmonary TB, in which ú1,000 patients were included, equal ally being effective); tapering occurred over 2 -8 weeks. Reappearance of hypersensitivity reactions following tapering (usurates of clearance of positive cultures were observed between the matched groups [15 -17, 20, 22 -24, 26] ; the other two ally rashes) was frequent, however, and the continuation of at least a minimal dose of corticosteroids for the entire course of studies split on which group cleared faster [19, 25] . These data were similar for the 40 patients in the two studies on primary therapy has on occasion been necessary. With the advent of newer, more varied, and non-cross-reacting antituberculous TB [58, 59] . It would appear that, given the adequacy of antibiotic therapy, there is no slower rate of culture conversion for drugs, the necessity of corticosteroid therapy for this indication should be unusual. corticosteroid-treated patients. The Madras study [26] is pertinent for its warning about the necessity for adequate antibiotic An unequivocally lifesaving indication for these agents is adrenal insufficiency secondary to glandular destruction due to therapy, which may be difficult to ensure in areas where multidrug-resistant TB is prevalent.
TB, a syndrome occurring in from 1% to 58% of patients with TB (depending on the population studied and how vigorously Most investigations were performed before rifampin was introduced. This agent, combined with isoniazid, has been so compromised adrenal function was sought) [83 -86] . ''Stress'' doses of corticosteroids should be administered if suspicion of effectively tuberculocidal that it could be posited that corticosteroids are not needed in the current era. Indeed, in the Madras hypoadrenalism arises, at least until the diagnosis is excluded. Attention should be given to the known suppressive effect of trial [26] , the trend to faster radiographically evident resolution when corticosteroids were added to rifampin-containing regirifampin on both exogenous and endogenous metabolism of corticosteroids, which has resulted in the precipitation of adremens did not reach significance (resolution was significantly faster in the group not given rifampin therapy). However, cortinal crises following administration by the unwary [87 -89] . costeroids were beneficial when added to rifampin-containing regimens in three other studies: a double-blind trial studying Recommendations pleural effusions [50] and both of the studies on tuberculous pericarditis by Strang et al. [43, 44] . No data addressing this Sufficient data (at least two adequately performed controlled studies) are available to make recommendations regarding the question are available from the trials on pulmonary or meningeal TB. Although the addition of corticosteroids to a rapidly adjunctive use of corticosteroid therapy for the following disease categories: tuberculocidal regimen that might prompt a greater local tissue reaction [3] makes sense and is supported by these more recent 1. Pulmonary TB. Adjunctive corticosteroid therapy can be used to relieve the severe systemic and respiratory morbidtrials, a final judgment on efficacy must await more trials using the contemporary regimens.
ity of far-advanced pulmonary TB. Radiographically evident abnormalities, other than cavities, usually resolve A recurrent objection to the use of corticosteroid therapy for tuberculous meningitis has been the known propensity of these faster with corticosteroid usage, although the significance to the patient is uncertain. No improvement in final endagents to reduce the diffusion of antibacterial agents into the subarachnoid space [75] . However, Kaojarern et al. [76] dempoints (chronic respiratory disease or death) can be expected. Given adequate chemotherapy (two or more effeconstrated essentially equivalent CSF concentrations when patients treated with and without adjunctive corticosteroids were tive antituberculous agents), adjunctive corticosteroid use does not appear to delay the time to conversion of sputum studied. Isoniazid, rifampin, pyrazinamide, and streptomycin levels were compared in CSF and serum for at least 6 weeks culture to negative. 
